Corey Centen
About Corey Centen
Corey Centen is the founder, president, and CTO of Bodyport, a company that developed the FDA-approved Bodyport Cardiac Scale to monitor heart failure patients and prevent hospital readmissions through advanced sensor technology and AI algorithms.
Corey Centen - Founder, President and CTO
Corey Centen is the Founder, President, and CTO of Bodyport. He drives the company’s mission to tackle complex chronic conditions by leveraging data from daily experiences to extract clinically actionable biomarkers. His approach aims to empower individuals to live free from the burdens of chronic health issues by providing innovative health monitoring solutions.
Achievements in Medical Technology
Corey Centen achieved a milestone by receiving U.S. Food & Drug Administration (FDA) 510(k) clearance for the Bodyport Cardiac Scale. This device integrates advanced sensor technology and AI-powered algorithms to identify a range of hemodynamic biomarkers. The cardiac scale transmits data over a cellular network to care teams, offering valuable insights into patients' conditions, thereby enabling efficient and effective management of heart failure.
Bodyport Cardiac Scale Development
Corey Centen developed the Bodyport Cardiac Scale to support individuals with heart failure, aiming to keep them healthier and out of the hospital. The scale collects data using state-of-the-art sensors and AI, delivering critical health information to care teams. This technology provides actionable data that helps in the proactive management of heart failure by monitoring daily biometrics.
Future Plans for Advanced Health Monitoring
Corey Centen plans to expand Bodyport's technology to include new biomarkers and algorithms. This initiative aims to improve the prediction and management of worsening conditions in patients with complex chronic diseases. Further developments will extend the technology to other cardiorenal conditions, such as chronic kidney disease, enhancing patient care and outcomes.
Clinical Collaborations
Corey Centen has collaborated with over 10 leading hospitals and healthcare systems across the U.S. for clinical studies. These partnerships are integral to validating the efficacy of the Bodyport Cardiac Scale and ensuring its readiness for broader clinical application. Such collaborations underline the importance of empirical data and clinical evidence in the development of healthcare technologies.